Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model‐Based Meta‐Analysis of American College of Rheumatology Response Criteria

银屑病性关节炎 荟萃分析 痹症科 医学 内科学 关节炎 肿瘤科
作者
Alan Maloney,Vivek Dua,Ghada F. Ahmed
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:115 (5): 1007-1014 被引量:3
标识
DOI:10.1002/cpt.3135
摘要

A model‐based meta‐analysis (MBMA) was conducted to compare the efficacy of bimekizumab with other psoriatic arthritis (PsA) treatment regimens using ≥ 20%/50%/70% improvements in American College of Rheumatology (ACR) criteria (ACR20/50/70) for patients with PsA. Forty‐nine trials of 16 drugs were identified in the literature, comprising 21,340 patients. Trial‐level covariates, including prior biologic use, concomitant methotrexate use, time since diagnosis, trial completion year, and active comparator were considered for exploratory models. The final model was selected using leave‐one‐out cross‐validation (LOO CV) to assess predictive performance based on prespecified criteria. LOO CV was conducted for 15 trials; the final model demonstrated that 91.5% (952/1,040) of the observed treatment differences, and 96.1% of the observed ACR20/50/70 response rates were within the 95% prediction interval (PI). Median ACR50 response rates (95% PI) at week 16 in biologic‐naïve patients were predicted to be 44% (40–49%) for bimekizumab 160 mg, among the highest of all treatments analyzed. Response rates for secukinumab 150 mg and risankizumab 150 mg were 28% (25–32%) and 27% (24–31%), respectively. The MBMA was also used to predict the probability of success (PoS) of potential head‐to‐head trials using ACR50 response as the end point with varying sample sizes: vs. secukinumab 150 mg, the PoS for bimekizumab 160 mg was 62% ( N = 200) and 90% ( N = 400). Versus risankizumab 150 mg, the PoS for bimekizumab 160 mg was 68% ( N = 200) and 94% ( N = 400). In summary, a predictive MBMA described ACR20/50/70 outcomes in PsA, allowing accurate and precise treatment comparisons and robust PoS calculations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jasper应助我爱金哥采纳,获得10
刚刚
顺利煎蛋发布了新的文献求助10
1秒前
1秒前
1秒前
北城发布了新的文献求助10
1秒前
1秒前
CDKSEVEN完成签到,获得积分20
2秒前
量子星尘发布了新的文献求助10
2秒前
3秒前
zhuanghj5发布了新的文献求助10
4秒前
绵绵球发布了新的文献求助100
4秒前
4秒前
世界上最后一只呜呜怪完成签到,获得积分10
4秒前
cc2713206完成签到,获得积分0
5秒前
九月发布了新的文献求助10
5秒前
5秒前
Jasper应助北城采纳,获得10
7秒前
A阿澍发布了新的文献求助10
7秒前
顺利煎蛋完成签到,获得积分10
7秒前
肖肖发布了新的文献求助10
8秒前
chengmin完成签到 ,获得积分10
8秒前
wei发布了新的文献求助50
8秒前
9秒前
10秒前
sunwen发布了新的文献求助10
10秒前
11秒前
12秒前
北城完成签到,获得积分10
13秒前
十三完成签到 ,获得积分10
14秒前
打打应助傲寒采纳,获得10
14秒前
小李吃小孩完成签到,获得积分10
14秒前
含蓄大雁完成签到,获得积分10
14秒前
15秒前
Livrik发布了新的文献求助10
16秒前
卢敏明发布了新的文献求助10
16秒前
李健应助俏皮的白柏采纳,获得10
17秒前
17秒前
很好关注了科研通微信公众号
18秒前
18秒前
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035